Major study: hydroxyurea reduces sickle cell mortality by 40 percent
In 1995, U.S. researchers published results of a major multi-center study showing that the compound hydroxyurea could cut in half the number of severe painful episodes patients with sickle cell anemia experience.
Now, an extension of that study shows that not only do patients on hydroxyurea have fewer crises, but they also have a significant survival advantage when compared to similarly affected patients who do not take the medication. Subjects treated with it overall showed 40 percent lower mortality than others.